CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Revenue:
Revenue	$ 801,536	$ 670,534		$ 366,260
Costs and operating expenses:
Cost of product revenue	345,830	279,280		156,634
Research and development	43,936	34,274		20,182
Selling, general and administrative	215,829	183,866		119,621
Contingent consideration	(28,729)	5,865		0
Total costs and operating expenses	576,866	503,285		296,437
Income from operations	224,670	167,249		69,823
Other (expenses) income:
Investment income	6,978	176		1,741
Interest expense	(1,162)	(11,278)		(10,768)
Amortization of debt issuance costs	1,815	1,436		1,365
Other expenses	(9,531)	(1,168)		(214)
Other expenses, net	(5,530)	(13,706)		(10,606)
Income before income taxes	219,140	153,543		59,217
Income tax provision (benefit)	33,181	25,252		(709)
Net income	$ 185,959	$ 128,291		$ 59,926
Earnings per share:
Basic	$ 3.35	$ 2.33		$ 1.14
Diluted	$ 3.24	$ 2.24		$ 1.11
Weighted average common shares outstanding:
Basic	55,460	55,015		52,554
Diluted	57,455	57,264		53,892
Net income	$ 185,959	$ 128,291		$ 59,926
Other comprehensive income (loss):
Foreign currency translation adjustment	(17,508)	(18,971)		17,112
Comprehensive income	168,451	109,320		77,038
Products
Revenue:
Revenue	801,183	670,319	[1]	366,136	[2]
Royalty and Other Revenue
Revenue:
Revenue	$ 353	$ 215		$ 124

[1] 2021 revenue for filtration products includes revenue related to Polymem from July 1, 2021, as well as BioFlex and NTM from December 16, 2021 through December 31, 2021. 2021 revenue for proteins products includes revenue related to Avitide from September 20, 2021 through December 31, 2021.

[2] 2020 revenue for filtration products includes revenue related to EMT from July 13, 2020, NMS from October 20, 2020, and ARTeSYN from December 3, 2020 through December 31, 2020.